A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

The US regulator has started a priority review of the injectable formulation of HIV-1 capsid inhibitor lenacapavir, which also has breakthrough status, and is due to deliver a decision on the ...

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the field following new study results showing a 96% reduction in HIV cases.

Lenacapavir was filed for U.S. approval for twice-yearly HIV prevention. A mid-2025 launch is anticipated, with access expected to reach 75% within six months. European submissions are under ...

“From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV ...

As it awaits FDA approval, Gilead is laying the groundwork for the launch of its antiretroviral drug lenacapavir as a pre-exposure prophylactic for HIV by mid-2025. The pharma made the announcement ...

Copyright: © 2025 Published by Elsevier Ltd. Implementation of lenacapavir for HIV prevention will require collective stewardship to achieve equitable roll-out. In ...

While PrEP pills have been an important tool in HIV prevention, we now have something potentially far more transformative: lenacapavir, recently named Science Magazine’s 2024 “Drug of the Year.” ...